Your browser doesn't support javascript.
loading
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
Goodwin, Craig M; Waters, Andrew M; Klomp, Jennifer E; Javaid, Sehrish; Bryant, Kirsten L; Stalnecker, Clint A; Drizyte-Miller, Kristina; Papke, Bjoern; Yang, Runying; Amparo, Amber M; Ozkan-Dagliyan, Irem; Baldelli, Elisa; Calvert, Valerie; Pierobon, Mariaelena; Sorrentino, Jessica A; Beelen, Andrew P; Bublitz, Natalie; Lüthen, Mareen; Wood, Kris C; Petricoin, Emanuel F; Sers, Christine; McRee, Autumn J; Cox, Adrienne D; Der, Channing J.
Afiliação
  • Goodwin CM; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Waters AM; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Klomp JE; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Javaid S; Program in Oral and Craniofacial Biomedicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Bryant KL; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Stalnecker CA; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Drizyte-Miller K; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Papke B; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Yang R; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Amparo AM; Charité Universitätsmedizin Berlin, Institute of Pathology, Laboratory of Molecular Tumor Pathology and Systems Biology, Berlin, Germany.
  • Ozkan-Dagliyan I; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Baldelli E; Berlin Institute of Health (BIH), Berlin, Germany.
  • Calvert V; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Pierobon M; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Sorrentino JA; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Beelen AP; Center for Applied Proteomics and Molecular Medicine, George Mason University, Fairfax, Virginia.
  • Bublitz N; Center for Applied Proteomics and Molecular Medicine, George Mason University, Fairfax, Virginia.
  • Lüthen M; Center for Applied Proteomics and Molecular Medicine, George Mason University, Fairfax, Virginia.
  • Wood KC; G1 Therapeutics, Research Triangle Park, North Carolina.
  • Petricoin EF; G1 Therapeutics, Research Triangle Park, North Carolina.
  • Sers C; Charité Universitätsmedizin Berlin, Institute of Pathology, Laboratory of Molecular Tumor Pathology and Systems Biology, Berlin, Germany.
  • McRee AJ; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Cox AD; Berlin Institute of Health (BIH), Berlin, Germany.
  • Der CJ; Charité Universitätsmedizin Berlin, Institute of Pathology, Laboratory of Molecular Tumor Pathology and Systems Biology, Berlin, Germany.
Cancer Res ; 83(1): 141-157, 2023 01 04.
Article em En | MEDLINE | ID: mdl-36346366
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article